Cocaine
Discover related
5 sources
Collated from PsychonautWiki, TripSit, Pharmacology, DrugCentral, DailyMed. Where sources differ (e.g. dosing), Compare shows them side by side.
Also known as Cocaine, Coke, Coca, Crack, Blow, Girl, White, Snow, Nose Candy, Yayo, Perico, Gear, ChariPW
Levamisole, a common cocaine adulterant, is linked to cocaine/levamisole-associated syndromes By 2017, 87% of cocaine seized and analyzed in the US contained levamisole.[1]PW
Insufflated
Route dataPsychonautWiki
| Threshold | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| 5 mg | 10–30 mg | 30–60 mg | 60–90 mg | 90 mg+ |
| Onset | 3–10 minutes |
|---|---|
| Come-up | 5–12 minutes |
| Peak | 7.5–16 minutes |
| Offset | 10–25 minutes |
| Total | 10–90 minutes |
Intravenous
Route dataPsychonautWiki
| Threshold | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| 2 mg | 2–5 mg | 5–10 mg | 10–15 mg | 15 mg+ |
| Onset | 3–5 seconds |
|---|---|
| Come-up | 1–2 minutes |
| Peak | 2–10 minutes |
| Offset | 1–5 minutes |
| Total | 5–15 minutes |
Oral
Route dataPsychonautWiki
| Threshold | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| 13 mg | 13–75 mg | 75–150 mg | 150–225 mg | 225 mg+ |
| Onset | 30–40 minutes |
|---|---|
| Come-up | 40–50 minutes |
| Peak | 60–180 minutes |
| Offset | 10–25 minutes |
| Total | 120–240 minutes |
Smoked
Route dataPsychonautWiki
| Threshold | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| 2.5 mg | 5–15 mg | 15–30 mg | 30–45 mg | 45 mg+ |
| Onset | 3–5 seconds |
|---|---|
| Come-up | 1–2 minutes |
| Peak | 2–10 minutes |
| Offset | 1–5 minutes |
| Total | 5–15 minutes |
Caution / uncertainPWTS
🧬 Receptor activityPHDC
| Target | Action | Affinity | Source | |
|---|---|---|---|---|
| Sodium-dependent dopamine transporter | — | Ki 43 nM | CHEMBL | TargetSodium-dependent dopamine transporter Action— AffinityKi 43 nM SourceCHEMBL |
| Sodium-dependent serotonin transporter | — | Ki 361.9 nM | CHEMBL | TargetSodium-dependent serotonin transporter Action— AffinityKi 361.9 nM SourceCHEMBL |
| Sodium-dependent noradrenaline transporter | — | Ki 392.6 nM | CHEMBL | TargetSodium-dependent noradrenaline transporter Action— AffinityKi 392.6 nM SourceCHEMBL |
| Serotonin 3 receptor (5HT3) (HTR3B) | Antagonist | 4.8 Ki | DRUGCENTRAL | TargetSerotonin 3 receptor (5HT3) (HTR3B) ActionAntagonist Affinity4.8 Ki SourceDRUGCENTRAL |
| Sodium-dependent dopamine transporter (SLC6A3) | Inhibitor | 7.5 Ki | DRUGCENTRAL | TargetSodium-dependent dopamine transporter (SLC6A3) ActionInhibitor Affinity7.5 Ki SourceDRUGCENTRAL |
| 5-hydroxytryptamine receptor 1B (HTR1B) | — | 5.47 Ki | DRUGCENTRAL | Target5-hydroxytryptamine receptor 1B (HTR1B) Action— Affinity5.47 Ki SourceDRUGCENTRAL |
| 5-hydroxytryptamine receptor 3A (HTR3A) | — | 5.71 Ki | DRUGCENTRAL | Target5-hydroxytryptamine receptor 3A (HTR3A) Action— Affinity5.71 Ki SourceDRUGCENTRAL |
| Alpha-1A adrenergic receptor (ADRA1A) | — | 5.68 Ki | DRUGCENTRAL | TargetAlpha-1A adrenergic receptor (ADRA1A) Action— Affinity5.68 Ki SourceDRUGCENTRAL |
| Cocaine- and amphetamine-regulated transcript protein (CARTPT) | — | — | DRUGCENTRAL | TargetCocaine- and amphetamine-regulated transcript protein (CARTPT) Action— Affinity— SourceDRUGCENTRAL |
| Dopamine transporter (SLC6A3) | — | 7.19 IC50 | DRUGCENTRAL | TargetDopamine transporter (SLC6A3) Action— Affinity7.19 IC50 SourceDRUGCENTRAL |
| Histamine H1 receptor (HRH1) | — | 5.67 Ki | DRUGCENTRAL | TargetHistamine H1 receptor (HRH1) Action— Affinity5.67 Ki SourceDRUGCENTRAL |
| Kappa-type opioid receptor (OPRK1) | — | 5.1 IC50 | DRUGCENTRAL | TargetKappa-type opioid receptor (OPRK1) Action— Affinity5.1 IC50 SourceDRUGCENTRAL |
| Muscarinic acetylcholine receptor M1 (Chrm1) | — | 4.21 Ki | DRUGCENTRAL | TargetMuscarinic acetylcholine receptor M1 (Chrm1) Action— Affinity4.21 Ki SourceDRUGCENTRAL |
| Potassium voltage-gated channel subfamily H member 2 (KCNH2) | — | 5.14 IC50 | DRUGCENTRAL | TargetPotassium voltage-gated channel subfamily H member 2 (KCNH2) Action— Affinity5.14 IC50 SourceDRUGCENTRAL |
| Sigma non-opioid intracellular receptor 1 (SIGMAR1) | — | 5.05 Ki | DRUGCENTRAL | TargetSigma non-opioid intracellular receptor 1 (SIGMAR1) Action— Affinity5.05 Ki SourceDRUGCENTRAL |
| Sodium channel alpha subunits; brain (Types I, II, III) (SCN1A) | — | 4.31 IC50 | DRUGCENTRAL | TargetSodium channel alpha subunits; brain (Types I, II, III) (SCN1A) Action— Affinity4.31 IC50 SourceDRUGCENTRAL |
| Sodium channel protein type 11 subunit alpha (SCN11A) | — | — | DRUGCENTRAL | TargetSodium channel protein type 11 subunit alpha (SCN11A) Action— Affinity— SourceDRUGCENTRAL |
| Sodium channel protein type 5 subunit alpha (SCN5A) | — | — | DRUGCENTRAL | TargetSodium channel protein type 5 subunit alpha (SCN5A) Action— Affinity— SourceDRUGCENTRAL |
| Sodium- and chloride-dependent GABA transporter 1 (SLC6A1) | — | 5.5 IC50 | DRUGCENTRAL | TargetSodium- and chloride-dependent GABA transporter 1 (SLC6A1) Action— Affinity5.5 IC50 SourceDRUGCENTRAL |
| Sodium-dependent dopamine transporter (Slc6a3) | — | 7.49 Ki | DRUGCENTRAL | TargetSodium-dependent dopamine transporter (Slc6a3) Action— Affinity7.49 Ki SourceDRUGCENTRAL |
| Sodium-dependent noradrenaline transporter (SLC6A2) | — | 5.57 Ki | DRUGCENTRAL | TargetSodium-dependent noradrenaline transporter (SLC6A2) Action— Affinity5.57 Ki SourceDRUGCENTRAL |
| Sodium-dependent serotonin transporter (SLC6A4) | — | 6.92 Ki | DRUGCENTRAL | TargetSodium-dependent serotonin transporter (SLC6A4) Action— Affinity6.92 Ki SourceDRUGCENTRAL |
| Transporter (Slc6a2) | — | 6.97 Ki | DRUGCENTRAL | TargetTransporter (Slc6a2) Action— Affinity6.97 Ki SourceDRUGCENTRAL |
Mechanism of actionPHDM
Cocaine produces anesthesia by inhibiting excitation of nerve endings or by blocking conduction in peripheral nerves. This is achieved by reversibly binding to and inactivating sodium channels. Sodium influx through these channels is necessary for the depolarization of nerve cell membranes and subsequent propagation of impulses along the course of the nerve. Cocaine is the only local anesthetic with vasoconstrictive properties. This is a result of its blockade of norepinephrine reuptake in the autonomic nervous system. Cocaine binds differentially to the dopamine, serotonin, and norepinephrine transport proteins and directly prevents the re-uptake of dopamine, serotonin, and norepinephrine into pre-synaptic neurons. Its effect on dopamine levels is most responsible for the addictive property of cocaine.
The presence and function of cannabinoid CB(2) receptors in the brain have been the subjects of much debate. /The investigators/ found that systemic, intranasal or intra-accumbens local administration of JWH133, a selective CB(2) receptor agonist, dose-dependently inhibited intravenous cocaine self-administration, cocaine-enhanced locomotion, and cocaine-enhanced accumbens extracellular dopamine in wild-type and CB(1) receptor knockout (CB(1)(-/-), also known as Cnr1(-/-)) mice, but not in CB(2)(-/-) (Cnr2(-/-)) mice. This inhibition was mimicked by GW405833, another CB(2) receptor agonist with a different chemical structure, and was blocked by AM630, a selective CB(2) receptor antagonist. Intra-accumbens administration of JWH133 alone dose-dependently decreased, whereas intra-accumbens administration of AM630 elevated, extracellular dopamine and locomotion in wild-type and CB(1)(-/-) mice, but not in CB(2)(-/-) mice. Intra-accumbens administration of AM630 also blocked the reduction in cocaine self-administration and extracellular dopamine produced by systemic administration of JWH133. These findings suggest that brain CB(2) receptors modulate cocaine's rewarding and locomotor-stimulating effects, likely by a dopamine-dependent mechanism.
Cocaine hydrochloride is a local anesthetic which blocks initiation or conduction of nerve impulses following local application; when applied topically to mucous membranes, the drug also produces intense vasoconstriction. When applied topically to the mucous membranes of the nose or mouth, cocaine reduces the acuity of smell or taste, respectively. Cocaine exerts an indirect adrenergic effect by interfering with the uptake of norepinephrine by adrenergic nerve terminals, and therefore potentiates the effects of catecholamines. The indirect adrenergic effect is apparently the mechanism by which the drug produces vasoconstriction and mydriasis. Cocaine has CNS stimulating effects. The drug is also markedly pyrogenic, augmenting heat production by stimulating muscular activity and decreasing heat loss through vasoconstriction.
Cocaine has multiple central and peripheral pharmacological actions. The action responsible for the rewarding property, and hence the abuse liability, of cocaine is an action in the dopaminergic synapse; in the rat the major set of critical dopaminergic synapses appears to be in the nucleus accumbens. Cocaine prolongs the activity of dopamine in the synapse by blocking the dopamine reuptake mechanism (which usually inactivates the transmitter by removing it from the proximity of its synaptic targets). This is an action shared with amphetamine; in addition to blocking the dopamine reuptake mechanism, amphetamine also augments dopaminergic function by augmenting dopamine release directly into the synapse. While amphetamine and cocaine have discriminable subjective effects, perhaps due to differences in rate of onset and metabolism or perhaps due to different side effects, cocaine shares its rewarding impact and abuse liability very closely with amphetamine. When drug access is unlimited, cocaine and amphetamine have the same ability to dominate behavior, reducing other behaviors such as feeding and sleeping and, in the process, reducing stress resistance to life threatening levels.
Cocaine is a potent inhibitor of dopamine reuptake and appears to release this neurotransmiter. Dopamine reuptake inhibition has been confirmed in a number of studies and is consistent with acutely increased dopamine neurotransmission. A further reflection of increased synaptic availability of dopamine is the finding of elevated 3-methoxytyramine but normal homovanillic acid concentrations after cocaine administration. Cocaine also causes reductions in brain dopamine concentrations with repeated administration. Cocaine elevates brain dopamine concentrations acutely, followed by reductions below normal levels several minutes later. Cocaine has also been shown to inhibit dopamine vesicle binding, thereby exposing /dopamine/ to intracellular metabolism.
For more Mechanism of Action (Complete) data for Cocaine (9 total), please visit the HSDB record page.
PharmacodynamicsPHDM
Cocaine is a local anesthetic indicated for the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities.
Pharmacokinetics
Half-lifePH
1 hour
The observed half life depends on the route of administration, dosage, and individual subject. It is of the order of 0.7 to 1.5 hours. After oral administration, it appears to be 0.8 hours, nasal administration, 1.25 hours, parenteral administration 0.7 to 0.9 hours.
Benzoylecgonine and ecgonine methyl ester, the major metabolites of cocaine, have half lives of 5-8 hours and 3.5-6 hours, respectively. /Cocaine metabolites/
The half-life is a very important parameter for estimating the time required to eliminate the drug in the body. It takes one half-life for plasma levels to fall to half of their original level. In the case of cocaine, it takes 1.5 hr for cocaine plasma levels to fall from 102 ng/mL. This is the same time that it takes for concentrations to fall from 51 ng/mL to 25.5 ng/mL. By five half-lives (7.5 hr) the plasma concentration of cocaine decreased from 102 ng/mL to 3.1 ng/mL, which is 3% of the original drug in the body. Almost all the drug (97%) will be eliminated by five half-lives. For reaching a certain drug level, an additional half-life will be required if the dose is doubled. For example, if cocaine is given at a dose of 40 mg, it will take two half-lives to reach the level of 51 ng/mL and six half-lives to reach the level of 3.1 ng/mL.
The biological half-life of cocaine is 0.5 to 1.5 hours.
For more Biological Half-Life (Complete) data for Cocaine (6 total), please visit the HSDB record page.
AbsorptionPHDM
Cocaine is absorbed from all sites of application, including mucous membranes and gastrointestinal mucosa. By oral or intra-nasal route, 60 to 80% of cocaine is absorbed.
Cocaine hydrochloride is absorbed from all sites of application, including mucous membranes and GI mucosa, and absorption may be enhanced in the presence of inflammation. In recreational cocaine users, the relative bioavailability of the drug, as determined by area under the plasma concentration-time curve (AUC), for a 2-mg/kg intranasal or oral dose of a 10% cocaine solution is the same; however, peak plasma concentrations are reportedly higher and occur sooner following oral administration than after intranasal administration. Following topical application of a 10% solution to the nasal mucosa, peak plasma cocaine concentrations occur within 15-120 minutes. Following topical application of cocaine hydrochloride solutions to mucous membranes, the onset of local anesthesia occurs within about 1 minute, is maximal within about 5 minutes, and may persist for 30 minutes or longer, depending on the dose and concentration used. /Cocaine hydrochloride/
Cocaine is rapidly and well absorbed from the nasal mucosa, gastrointestinal mucosa, pulmonary alveoli and by direct intravenous injection ... .
Cocaine is absorbed by all routes of administration, but the proportion absorbed depends on the route. After oral administration, cocaine appears in blood after about 30 minutes, reaching a maximum concentration in 50 to 90 minutes. In acid medium, cocaine is ionized, and fails to cross into cells. In alkaline medium, there is less ionization and the absorption rapidly increases. By the nasal route, clinical effects are evident 3 minutes after administration, and last for 30 to 60 minutes, the peak plasma concentration being around 15 minutes. By oral or intra-nasal route, 60 to 80% of cocaine is absorbed. By inhalation, the absorption can vary from 20 to 60%, the variability being related to secondary vasoconstriction. Freebase does not undergo first-pass hepatic metabolism, and plasma concentrations rise immediately to 1 to 2 mg/L. The effects on the brain occur very rapidly, after about 8 to 12 seconds, are very violent ("flash"), and last only 5 to 10 minutes. By the intravenous route blood concentrations rise to a peak within a few minutes.
When smoked, absorption of the free base from the lung is rapid and efficient, producing concn in plasma of more than 900 ng/mL; peak values of 150 to 200 ng/mL are reached 30 to 40 minutes after the inhalation of 96 mg of crystalline cocaine hydrochloride.
For more Absorption, Distribution and Excretion (Complete) data for Cocaine (8 total), please visit the HSDB record page.
MetabolismPH
Hepatic. Cocaine is metabolized to benzoylecgonine and ecgonine methyl ester, which are both excreted in the urine. In the presence of alcohol, a further active metabolite, cocaethylene is formed, and is more toxic then cocaine itself.
The metabolism of cocaine is complex and dependent on both genetic and acquired factors. Three major pathways of cocaine metabolism are well described. Cocaine undergoes N-demethylation in the liver to form norcocaine, a minor metabolite that rarely accounts for more than 5% of drug. However, norcocaine readily crosses the blood-brain barrier and produces clinical effects in animals that are quite similar to cocaine. Nearly half of a dose of cocaine is both nonenzymatically and enzymatically hydrolyzed to form benzoylecgonine (BE). the BE is inject into animals, some reports suggest that it is virtually inactive, while other studies demonstrate cerebral vasoconstriction and seizures. When with injected directly into the cerebral ventricles or applied to the surface of cerebral arteries, BE is a potent vasoconstrictor. Although BE tranverses the blood-brain barrier poorly, the potential effects ar of concern as some BE is probably formed form cocaine that has already entered the central nervous system (CNS). In vitro, BE has little or not effect on cardia sodium or potassium channels. Finally, plasma cholinesterase (PChE) and other esterases metabolize cocaine to ecgonine methyl ester (EME). In normal individuals, between 32% and 49% of cocaine is metabolized to EME. Like BE, EME crosses the blood-brain barrier poorly. Although many authors state that EME has little or no pharmacologic activity, diverse animal models demonstrate contradictory results, concluding that EME is a vasodilator, sedative, anticonvulsant, and protective metabolite against lethal doses of cocaine.
1 to 9% of cocaine is eliminated unchanged in the urine, with a higher proportion in acid urine. The metabolites ecgonine methyl ester, benzoylecgonine, and ecgonine are recovered in variable proportions which depend on the route of administration. At the end of 4 hours, most of the drug is eliminated from plasma, but metabolites may be identified up to 144 hours after administration. Unchanged cocaine is excreted in the stool and in saliva. Cocaine and benzoylecgonine can be detected in maternal milk up to 36 hours after administration, and in the urine of neonates for as much as 5 days.Freebase cocaine crosses the placenta, and norcocaine persists for 4 to 5 days in amniotic fluid, even when it is no longer detectable in maternal blood.
Cocaine metabolism takes place mainly in the liver, within 2 hours of administration. The rate of metabolism varies according to plasma concentration. There are 3 routes of bio-transformation: the major route is hydrolysis of cocaine by hepatic and plasma esterases, with loss of a benzoyl group to give ecgonine methyl ester. Esterase activity varies substantially from one subject to another. The secondary route is spontaneous hydrolysis, probably non-enzymatic, which leads to benzoylecgonine by demethylation. The final degradation of cocaine, which is a sequel to both the principle and secondary routes of metabolism, leads to ecgonine. N-demethylation of cocaine is a minor route leading to norcocaine. The principle metabolites are therefore benzoylecgonine, ecgonine methyl ester, and ecgonine itself, which are inactive; and norcocaine which is active, and may be relevant after acute intoxication. In the presence of alcohol, a further active metabolite, cocaethylene is formed, and is more toxic then cocaine itself. ...
Cocaine is hydrolyzed rapidly by liver and plasma esterases to ecgonine methyl ester, which accounts for 30% to 50% of of the parent product. Nonenzymatic hydrolysis result in the formation of the other major metabolite, benzoylecgonine (approximately 40% of the parent product). Minor metabolites, norcocaine, and ecgonine account for the other degradation products.
Hepatic. Cocaine is metabolized to benzoylecgonine and ecgonine methyl ester, which are both excreted in the urine. In the presence of alcohol, a further active metabolite, cocaethylene is formed, and is more toxic then cocaine itself.
Half Life: 1 hour
Plan a dose of Cocaine
Loading the fact-sheet…
Logging a dose needs somewhere to keep it. Start a free session — no signup; it and everything in it expire in 7 days.
External links
Fact-sheets from PsychonautWiki. Harm-reduction reference only — not medical advice.